Related Experiment Video

Updated: Jan 28, 2026

Seven Steps to Stellate Cells
06:40

Seven Steps to Stellate Cells

Published on: May 10, 2011

34.7K

Alogliptin alleviates liver fibrosis via suppression of activated hepatic stellate cell

Hanyan Zhang1, Dandan Sun2, Guanzhen Wang2

  • 1School of Pharmacy, Nanchang University, 461 Bayi Road, Nanchang, 330006, China.

Biochemical and Biophysical Research Communications
|February 25, 2019
PubMed

Insights

Alogliptin, a DPP4 inhibitor, shows potential in treating liver fibrosis by suppressing hepatic stellate cell activation. This study demonstrates its anti-fibrotic effects in vitro and in vivo, suggesting DPP4 as a novel therapeutic target.

Area of Science:

  • Hepatology
  • Pharmacology
  • Cell Biology

Background:

  • Liver fibrosis is a common consequence of chronic liver diseases with limited effective treatments.
  • Dipeptidyl peptidase-4 (DPP4) inhibitors, like alogliptin, are used for type 2 diabetes and show potential liver-protective effects.
  • The anti-fibrotic impact of alogliptin on liver fibrosis progression remains unclear.

Purpose of the Study:

  • To investigate the anti-fibrosis effects of alogliptin.
  • To explore alogliptin's mechanism in modulating hepatic stellate cell activation.
  • To assess alogliptin's therapeutic potential for liver fibrosis.

Main Methods:

  • In vitro: Assessed alogliptin's effect on LX-2 cells challenged with transforming growth factor-β (TGF-β).
  • In vivo: Evaluated alogliptin's impact on liver injury, steatosis, and fibrosis in ob/ob and CCl4-induced mouse models.

Main Results:

  • Alogliptin suppressed LX-2 cell activation in vitro.
  • Chronic alogliptin treatment reduced hepatic steatosis and liver injury in ob/ob mice, delaying fibrosis progression.
  • Alogliptin significantly alleviated liver fibrosis in a CCl4-induced mouse model.

Conclusions:

  • Alogliptin negatively modulates hepatic stellate cell (HSC) activation, contributing to liver fibrosis alleviation.
  • Alogliptin demonstrates therapeutic potential for liver fibrosis.
  • DPP4 inhibition represents a novel therapeutic strategy for liver fibrosis.
Keywords:
AlogliptinDPP4Hepatic stellate cellLiver fibrosis

More Related Videos

Author Spotlight: Advancing Hepatic Fibrosis Diagnosis Using Magnetic Resonance Elastography and AI06:09

Author Spotlight: Advancing Hepatic Fibrosis Diagnosis Using Magnetic Resonance Elastography and AI

Published on: July 21, 2023

1.9K
Generation of a Humanized Mouse Liver Using Human Hepatic Stem Cells11:44

Generation of a Humanized Mouse Liver Using Human Hepatic Stem Cells

Published on: August 29, 2016

11.5K

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
193
Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
868
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
228
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
270
Hepatic Portal System01:21

Hepatic Portal System

The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
5.8K
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
520